Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
465 Leser
Artikel bewerten:
(0)

Connected technology solutions dramatically improve medication adherence, according to new study from Philips

Finanznachrichten News

-- 96 percent of chronic disease patients stay on track with daily medication when using connected dispensing technology

-- Data analysis of more than 1,300 elderly patients with chronic conditions shows Philips Medido dispensing solution improves adherence

AMSTERDAM, June 1, 2016 /PRNewswire/ --Royal Philips(NYSE: PHG; AEX: PHIA) today announced new study results demonstrating the use of a connected medication dispensing technology can greatly benefit patients with chronic conditions, helping them better comply with long-term therapy. Over the span of one year, user data from more than 1,300 patients in the Netherlands was analyzed, showing 96% of patients using Philips Medido, a connected medication dispensing solution, were adherent to their medication schedule. Data from the study also showed that patients using Medido stayed adherent to long-term therapy over time, showing little or no change in adherence over the course of the year.

Infographic - http://photos.prnewswire.com/prnh/20160531/373807-INFO
Photo - http://photos.prnewswire.com/prnh/20160531/373805
Logo - http://photos.prnewswire.com/prnh/20140122/NE50581LOGO

Successful treatment with prescription medication requires consistent use over time. Studies have shown that during the treatment of chronic illnesses approximately 50% of patients do not adhere to their physician's long-term therapy recommendations [1,2]. While patients rely on their medications to keep them healthy and help them manage chronic conditions, complex medication schedules can often lead to mistakes, such as missed doses, incorrect amounts, or taking medications at the wrong time. Through a connected medication dispensing solution like Medido, patients living with chronic conditions can better manage their medication schedules, resulting in higher medication adherence and reduced costs of care.

"Proper medication adherence is such a crucial part to managing a chronic illness, and yet the more complicated a patient's care plan, the harder it can be to keep track of pills, doses, and the times they need to take their medication," said Kimberly O'Loughlin, Senior Vice President and General Manager of Home Monitoring, Philips. "By providing patients and caregivers with a solution that simplifies this part of the care process, they're able to feel more independent and secure in their care, and feel more confident aging in the comfort of their own homes."

The study looked into 881,000 medication moments of 1,379 patients in the Netherlands who on average took three doses per day. Key data and findings from the study include:

  • 96% of patients using Medido had a medication adherence rate over the World Health Organization's (WHO) standard of 80%.
  • Patients who required two or more medication doses per day maintained an adherence rate at around 94% with Medido.
  • Medication adherence remained consistent over time, with no significant differences during the yearlong study.

In addition to improving medication adherence, connected technology solutions can have a significant economic impact. Earlier study findings conclude that an estimated costs saving of up to 40% per patient could be achieved for specific groups of patients when connected dispensing solutions are part of the patient's regimen [3].

Philips Medido is an innovative home medication dispensing service designed to support chronically ill patients and care providers. When the patient's scheduled medication time arrives, the dispenser automatically reminds them, ensures that the correct medication is being released at the correct time and then releases and opens individual pouches according to the patient's prescribed regimen. The solution monitors removing medication from the dispenser and remotely alerts nursing staff when medication is not taken from the device, helping to streamline the normally time-consuming task of medication management and allowing them to focus on additional care issues.

Medido is currently available in the Netherlands, with additional launches expected in the U.S. and Europe later this year. For more than 40 years, Philips has been a leader in connected home health solutions with its Lifeline business, helping seniors live more safely and independently. Last year, Philips launched CareSage, a predictive analytics engine that helps care providers remotely manage at-risk patients and predicts whether a patient will need emergency transport in the next 30 days.

Philips will also be showcasing its latest connected health software, solutions and services at eHealth Week 2016 in Amsterdam. For more information on Philips presence at eHealth Week, please visit: www.philips.nl/ehealthweek.

[1] Sabaté E, et al. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization 2003.
[2] Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clinic Proceedings 2011; 86 (4): 304-314.
[3] Based on calculations for a patient receiving two combined-care visits and one medication-assistance-only visit a day in the Dutch context. This calculation was not part of the adherence data study. More info can be found in the white paper "Medido, a smart medication dispensing solution, shows high rates of medication adherence and potential to reduce cost of care" http://tinyurl.com/hprpocy

For further information, please contact:
Kathy O'Reilly
Philips Group Communications
(o) 978-659-2638 (mobile) 978-221-8919
Kathy.oreilly@philips.com
Twitter: @kathyoreilly

Joost Maltha
Philips Communications Healthcare Informatics, Solutions and Services
Tel. +31 6 10 55 8116
E-mail: joost.maltha@philips.com
Twitter: @joostmaltha

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Headquartered in the Netherlands, Philips' health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 69,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

© 2016 PR Newswire
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.